Pall Corp

Pall — RW Baird Industrial Conference 2014

52 slides from Pall's conference presentation, Nov 10, 2014

  1. Slide 1: Pall Corporation: Innovative technology. Winning strategy. Delivering value.

    Pall Corporation Better Lives. Better Planet. Innovative technology. Winning strategy. Delivering value. Larry Kingsley Chairman & CEO, Pall Corporation RW Baird Industrial Conference November 10, 2014

  2. Slide 2: Forward-looking statements

    ‘The meters discesed in this pesentaton contin fowarclookng statements’ as definedin the Private Secures Ligation Reform Act of 1005, Forwarce loalang statements are hoe nat edaress acvite, evens or developments hat the Company or management ntencs, expects projects, beieves or anicipates ‘ler tay a

  3. Slide 3: Agenda

    Agenda 12:15 12:20pm _Larry Kingsley — Introduction 12:20 - 12:45pm Ruby Chandy — Pall Industrial + 12:45—1:10pm Yves Baratelli — Pall Life Sciences *1:10-1:35pm Martin Smith - Pall Technology + 1:35 - :40pm —_Larry Kingsley - Conclusion 1:40- 2:00pm Q&A 2 Pal Corporation

  4. Slide 4: Pall Solutions and highly attractive business model

    = Pall Solutions: ” ~ We filter and purify valuable fluids ~ We protect valuable equipment and processes ~ We recover valuable solids = Highly Attractive Business Model ~ Differentiated, high-technology products Nearly 90% of sales from consumables Strong moat z Focused on high-growth end markets so

  5. Slide 5: Revenue and Operating Profit

    Revenue and Operating Profit FY 2014 Revenue Operating Margin Progression Life Sciences Industrial 20% Consumables Consumables tesy 170% 177% os $1,329) 10% $1,115 (49% tay 19% 10% om Life Sciences Indus om Systems Systems 20102011202 201s zat $125 /+19% $220/-8% Life Sciences: $1,454/+11% Sosisntop

  6. Slide 6: Pall Industrial

    Pall Corporation Better Lives. Better Planet. Pall Industrial Ruby Chandy President, Pall Industrial RW Baird Industrial Conference November 10, 2014

  7. Slide 7: Our Solutions: Pall Differentiators

    Our Solutions: Pall Differentiators: = We filter and purify valuable fluids = Customer intimacy = We protect valuable downstream « Deep applications knowledge assets and environment « Innovation * We retrieve valuable components = Global reach and support = We help our customers optimize their proce

  8. Slide 8: Process Technologies, Aerospace, Microelectronics

    Process Technologies Aerospace Microelectronics mY - Markets Markets Markets * Oil and Gas = Commercial aerospace * Semiconductors + Chemicals * Miltary aerospace * Displays * Power Generation + Marine * Data storage + Mining * Ink jot * Drinking / industrial / mobile water Focus Areas = Photovoltai

  9. Slide 9: Pall Industrial Global Trends and Drivers

    Pall Industrial Global Trends and Drivers Higher Consumerism in Emerging Markets By 2020 + 4.Bbb people reach middle class + 65% of growths in nciaiChina Impact to Pall + High pastes ang energy consumgtion * Data consumption growth + Growth in Commercial Aerospace New Infrastructure in Developed Eco

  10. Slide 10: FY 2014 Pall Industrial Global Revenue

    FY 2014 Pall Industrial Global Revenue Revenue By Market Revenue By Region Process Microelectronics Asia Technologies _ sags $576 +18% 0% ”” Rerospace Systems $236 $220 “8% Nise eaten eee Pall Corporation

  11. Slide 11: Industry Dynamics

    Industry Dynamics = Energy - Growth in oil and natural gas sector driving downstream expansion ‘= Machinery and Equipment - Expansion in auto manufacturing and in-plant asset utilization Focus Initiatives = Leverage advantaged applications Innovate to expand — unconventional oil and gas = lube & hyd

  12. Slide 12: Process: Investing in Growth Applications

    Process: Investing in Growth Applications Ethylene Manufacturing Shale oil and gas feedstocks = 150 projects; $100bb capex = Production of natural gas and liquids be 4H growing at >10% CAGR globally i = Driving $81bb in chemical output = $31bb 3 year investment in separations- | 24m, + — intensive e

  13. Slide 13: Aerospace Strategy

    “| Aerospace Strategy Industry Dynamics ~ Lowest cost solutions ~ Increased safety and reliability ~ Sustainable performance Focus Initiatives = Expand channels through ‘Supplemental Type Certificate (STC) product acceptances = Focused innovation and PUREair product expansion = Expand maintenance, r

  14. Slide 14: Pall Aerospace PUREair Products

    Pall Aerospace PUREair Products wth contaminant = Vortex tube systems: 4” generation technology tn generator resulting in 2% better overall engine performance — Light weight nano-technology materials, — Optimized tube geometry * Dry barrier filters: advanced synthetic media resulting in 40% lower we

  15. Slide 15: Industry Dynamics

    Industry Dynamics * Increasing chip complexity drives Pall innovation for cleaner and more retentive products Focus Initiatives + Grow strategic account share by becoming specified at advanced nodes * Continue to develop leading edge semiconductor- enabling technologies — New membranes and media — I

  16. Slide 16: MicroE: Investing in Innovation and Operations Enablement

    MicroE: Investing in Innovation and Operations Enablement Tsukuba, Japan * State-of-the-Art Manufacturing to serve Asia = ISO Class 1 Clean Room in Tsukuba, Japan = Customer Visits: “Tsukuba facility now looks like a Semiconductor Fab” Tailored application-specific solutions from membrane to device

  17. Slide 17: Pall Industrial Strategy

    | Pall Industrial Strategy 25% Growth-Fueled Leverage s growth 20% ; 20% coe = Innovation eee * Share gain in major 184% 10.8% ee accounts 15% | 43.7% 14.0% * Penetration in high growth regions = Continued focus on cost = efficiency o% o% FY14FYI2) FYI3. | FYI4 = FYIS—-FY16.FY17 Goal ‘Segment Margin

  18. Slide 18: Pall Life Sciences

    Pall Corporation Better Lives. Better Planet. Pall Life Sciences Yves Baratelli President, Pall Life Sciences RW Baird Industrial Conference November 10, 2014

  19. Slide 19: Pall Life Sciences Overview

    Pall Life Sciences Overview Our Filtration Solutions * We filter & purify valuable biological fluids = We protect patients from pathogens * We help our customers optimize their processes Pall Differentiators * Customer intimacy = Deep applications and regulatory knowledge = Innovation * Global reach

  20. Slide 20: Life Sciences markets: Process, Laboratory, Medical, Food & Beverage

    Process * Biotech * Biologics (Vaccines & Plasma) * Classic Pharmaceuticals Process Monit = Pharma QC * Protein Characterization ring Laboratory Research Tools * Core Lab * OEM Diagnostics/Materials * Laboratory QC OEM Healthcare * Filter Device (OEM) * Cell Therapy (OEM) * Cardiovascular (OEM) * In

  21. Slide 21: Life Sciences Market Drivers and Growth Potential

    Life Sciences Market Drivers and Growth Potential Growth in Biological-Based Drugs & Manufacturing By 2020 * Biologics spend to reach $300bb" * Reduced development time for biological drugs and reduced COGS required Impact to Pall * Focus on complete solutions to cover the full biological drug devel

  22. Slide 22: FY 2014 Pall Life Sciences Global Revenue

    FY 2014 Pall Life Sciences Global Revenue Revenue By Market Revenue By Region BioPharmaceuticals Europe ra $743 +12% 13% Food & Beverage y's $185 : , Systems 36% ve Americas $125 Medical +10% +13% $226 +7% Total Life Sciences $1,454; +11% ‘reareten of No. GAAP Francs Moone in is proeeson oth GAAP Ge

  23. Slide 23: Biologics are relieving pain and suffering or even curing diseases

    Biologics are relieving pain and suffering or even curing diseases that a decade or two ago were considered lethal Market Trend: = Highly targeted medicine based on “large” proteins = Seven of the Top10 selling drugs are protein-based = CAGR until 2020 is high single-digit for protein- based drugs v

  24. Slide 24: Where does Pall generate revenue?

    Where does Pall generate revenue? Through partnership with customers from discovery to production Ss Scale up and small scale Commercial Scale manufacturing (clinical trials) Manufacturing Discovery and process development tools = 10 - 20 years from discovery to eS full commercialization! Si | x Pal

  25. Slide 25: Biologics Manufacturing and Regulatory Processes

    Biologics Manufacturing and Regulatory Processes * Multiple step process with fod 7 filtration and separation boca) BS i ja. gu requirements at each stage = Driven by manufacturing volume and the number of steps in each process * Increasing adoption of Single-Use Technology Cel Separation & Clrfcato

  26. Slide 26: Grow Consumables Business

    Grow Consumables Business = Working closely with customers, leveraging our application, process, and regulatory know-how * Geographic expansion * Leverage SUT acquisitions (Medistad, SoloHill, and ATMI LS) ‘Singin Fit Modus 2 m intr Systm gaa smmeten etre sppbontons = Provide end-to-end solutions Br

  27. Slide 27: Medical Strategy

    Medical Strategy Pall Medical Direct Pall Medical OEM +2 e Water Hospital Surgical Gas Cell Therapy = Leverage strong position as a niche provider of Protection Products to Patient + Geographic expansion, including OEM channel ) = Deploy technical know- | {A how to new applications [ targeting reduc

  28. Slide 28: Geographic expansion; Food & Beverage

    = Geographic expansion sha | | jing _| * Food safety / quality Clarification ps Purification pp Final Filtration control Separation, concentration, Polishing, Concentration DP Adsorption, “Store 2, 0 Service Media Management / Process Control & Monitoring Beer . Soe ] Changing the game > i * Technol

  29. Slide 29: Technology

    Pall Corporation Better Lives. Better Planet. Technology Martin Smith, PhD Chief Technology Officer RW Baird Industrial Conference November 10, 2014

  30. Slide 30: Vision for Technology

    Vision for Technology: “Product Development Engine” that quickly and effectively generates robust, differentiated, quality products meeting customers’ needs and contributing significantly to our growth and margin with minimal capital requirements » Pal Corporation

  31. Slide 31: Investing in Innovation

    Investing in Innovation R&D Spend Recent Examples $120) pall ida $103 = We introduced 33 new $100 F $94 B products in FY 2014 while +9% taking steps to rationalize 14% our current product portfolio. $81 $83 + $80 9 $69 H17% oe $60 7 A J) ats 20 Soren Bioreactor or otmammaton $40 7 | t] ; ce wo | jhe

  32. Slide 32: Fundamentals of Filtration

    Fundamentals of Filtration = Media is the functional entity driving performance specificity to any filtration & separations event: — Size exclusion — Adsorption (e.g. charge interactions) — Concentration — Molecule rejection or repellency = Approximately % of all Pall revenue is generated by product

  33. Slide 33: Media & Materials — Enabling Pall Product Differentiation

    Media & Materials — Enabling Pall Product Differentiation Underlying Media Technologies Membranes Polymer Fil Ceramics Inorganic Fibers Value Added Enhancements Feeding 100s of Unique Formats and End User Applications PATENTS ® Pal Corporation

  34. Slide 34: Taking share while building the moat

    “Taking share while building the moat” Competition Pall Position Product Channel Applications Regulatory Excellence in Novel Filter Formats/IP Media IP Ye Ultimate Barriers « Pall Corporation

  35. Slide 35: Innovation is Accelerating at Pall

    Innovation is Accelerating at Pall 274 2010 2011 2012 2013 2014 ‘Invention Disclosures Submitted = Original Patent Applications Filed >60% of Pall 2014 patent filings represent new Media structures, chemistry and process treatments ry Pal Corporation

  36. Slide 36: Pall Materials Science

    Pall Materials Science — Driving to Game Change Performance 2014-2018 The Age of Technology sae Total Materials Consolidation Be Drive From Transformation Status Quo Enterprise Efficiency yption js scien? Ss material atrue % Pal Corporation

  37. Slide 37: Materials Science Leadership is Grounded in Technology Fundamentals

    Materials Science Leadership is Grounded in Technology Fundamentals Differentiated Performance Process Properties ” Pal Corporation

  38. Slide 38: Media R&D Evolution

    Media R&D Evolution is Dictated bi Market Trend Requirements ee Pall Medi Market Need: S = Faster Growing oa @ = Cleaner Teolnex = () Low Fouling Sse Application Specific Device Compatible Regulatory Compliant Measurable Controlled & Resistant Materials a Internal Infrastructure and nae Technology C

  39. Slide 39: A World Class Development Chain

    A World Class Development Chain Research Development Manufacturing 2. aii is New materials mobilization Invention is only as good as the ensuing development stages Full interconnectivity between Research, Development and Manufacturing groups Manufacturing impact is woven into our invention cadence —

  40. Slide 40: Keys to Winning in the Filtration Space

    Retention Keys to Winning in the Filtration Space = Deep understanding of the customers’ needs 1 Category * Filtration media with category winning performance * Surface chemistry * Metrology to guide product development and validate performance * Geometry for highest effective filtration area * Devi

  41. Slide 41: Novel Pall Materials — Break Out Filtration Performance

    Novel Pall Materials — Break Out Filtration Performance Self Assembly expected to drive new 70 performance curve * Step out flux vs. retention + Smaller pore sizes, Polymer flexibility * Greater manufacturing consistency 600 500 25 Pall Patent Applications Filed in 2014 400 300 Performance # patents

  42. Slide 42: Best in Class Filter Design

    Best in Class Filter Design — Research and Development * Novel media housed within novel filter formats (‘media packaging’) = Right Media + Right Filter = Optimized Application Performance * Many functional considerations — polymers, sealing, integrity testing, applications claim support = End user

  43. Slide 43: State of the Art Technology Infrastructure

    State of the Art Technology Infrastructure Full pilot line capabilities Automated testing and metrology High throughput platforms Microscopy In situ filter imaging 3D Printing & rapid prototyping Proprietary methods and analytics Development pace, accuracy and informed decision-making ‘8 Pal Corpora

  44. Slide 44: R&D Investment Focus

    R&D Investment Focus * Innovative media with category winning performance 1 Gatogory + Easy to use, innovative filter and device formats = Instrumentation that enables further BioPharm penetration = State of the art metrology Throughput = Expand single-use systems “ Pal Corporation

  45. Slide 45: Pall Corporation: Innovative technology. Winning strategy. Delivering value.

    Pall Corporation Better Lives. Better Planet. Innovative technology. Winning strategy. Delivering value. Larry Kingsley Chairman & CEO, Pall Corporation RW Baird Industrial Conference November 10, 2014

  46. Slide 46: Vision Forward: Industry Best in Class

    ir Vision Forward: Industry Best in Class Acquisitions Improving Capital @ Industry Efficiency Leading @ Customer Accelerating Service @ Growth Metrics = Share Gain @ Reducing Focus on high-growth Cost To Markets Serve 46 Driving Return on Capital Pall Corporation

  47. Slide 47: Pall Corporation Better Lives. Better Planet.

    Pall Corporation Better Lives. Better Planet.

  48. Slide 48: Pall Corporation Better Lives. Better Planet.

    Pall Corporation Better Lives. Better Planet.

  49. Slide 49: Appendix: Full Year Industrial Sales By Market & Technology

    ix: Full Year Industrial Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Full Year Full Year FY14 FY14 Ful Year | Estimated | Estimate FY14 __| Impact of FX_| Excluding EX Ful Year | % Change FY13 Excluding FX) Consumables Sales: Process Technologies | $ 576,062| $ (5,969)

  50. Slide 50: Appendix: Full Year Life Sciences Sales By Market & Technology

    ix: Full Year Life Sciences Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Full Year Full Year FY14 FY14 FulYear | Estimated | Estimate | FullYear | % Change FY14 _| Impact of FX_| Excluding FX| __FY13__| Excluding FX Consumables Sales: BioPharmaceuticals $ 917,542) $ 5,5

  51. Slide 51: Appendix: Full Year Sales By Segment & Region

    Appendix: Full Year Sales By Segment & Region Reconciliation of Non-GAAP Financial Measures Full Year Full YEar FY FY14 Estimated Estimate | Full Year Impact of FX__| Excluding FX|__FY13 Life Sciences Sales: Americas $495,132 (8,297) |$ 443,429 § 416,170 6.5% Europe 742,612 30,222 712.290) 627,647 1

  52. Slide 52: Appendix: Full Year Operating Profit

    Appendix: Full Year Operating Profit Reconciliation of Non-GAAP Financial Measures Full Year Full Year FulYear | Ful Full Yee FY14 FY: FY11 FY10 Life Sciences segment profit $357,129 319,271 | $319,312] $292,503 | $284,190 Industrial segment profit 219,172 214,798 198,747 | 182,749 | 155,37 Total se

Pall — RW Baird Industrial Conference 2014 on 6ix